Open an account

Citius Pharmaceuticals

CTXR · NASDAQ

$0.4175−$0.0103 (−2.41%)TodayMarket closed ·
Prev close $0.4278

About CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Employees
23
Headquarters
Cranford, New Jersey
Listed
Aug 3, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
citiuspharma.com

CTXR key statistics

Market cap
11.46M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
192.18K
Volume
187.99K
Open price
$0.434
High today
$0.4363
Low today
$0.4175
52 Week high
$2.19
52 Week low
$0.4142

Citius Pharmaceuticals (CTXR) at a glance

Citius Pharmaceuticals (CTXR) last traded at $0.4175, with a market cap of 11.46M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.4175 and $0.4363. The current price is 0.0% above the day's low and 4.3% below its high.

Volume so far is 187.99K shares, in line with the average of 192.18K shares a day.

Over the past year Citius Pharmaceuticals has ranged from $0.4142 to $2.19, and now sits 0% of the way up that range.

Citius Pharmaceuticals met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q4 FY25 it reported -$0.72 per share against an estimate of -$0.4964.

The average analyst price target is $4.08, 877.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $4.08
Low
$4.04
Now
$0.4175
High
$4.20

CTXR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 18.3% on average.

  1. Q1 FY24: reported -$1.50 per share against an estimate of $3.32
  2. Q2 FY24: reported -$1.25 per share against an estimate of -$1.53
  3. Q3 FY24: reported -$1.50 per share against an estimate of -$1.27
  4. Q4 FY24: reported -$1.59 per share against an estimate of -$1.53
  5. Q1 FY25: reported -$1.30 per share against an estimate of -$0.5882
  6. Q2 FY25: reported -$1.27 per share against an estimate of -$0.391
  7. Q3 FY25: reported -$0.80 per share against an estimate of -$0.6018
  8. Q4 FY25: reported -$0.72 per share against an estimate of -$0.4964

CTXR news

  • Press releasePRNewswire

    Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

  • Press releasePRNewswire

    Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

  • Press releasePRNewswire

    Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

  • Press releasePRNewswire

    Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releasePRNewswire

    Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Similar companies

Companies in the same industry as Citius Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.